抗高血压药联合用药分析

Analysis of combined application of anti-hypertensive drugs

目的:探讨临床中抗高血压药联合用药的特点和合理性。方法:对我院2010年1月-2011年1月收治的抗高血压药联合用药460例病历,按照联合用药的方案、品种、类别和临床疗效调查分析。结果:二联和三联用药是联合用药的主要形式,分别占64.13%和33.26%,其临床平均有效率分别为85.42%和81.70%。二联联合用药中,以钙拮抗剂(CCB)+血管紧张素转化酶抑制剂(ACEI)、CCB+β-受体拮抗剂及ACEI+β-受体拮抗剂为主,三联联合用药中,以ACEI+CCB+利尿剂、ACEI+CCB+β-受体拮抗剂为主。CCB,ACEI及血管紧张素受体拮抗剂(ARB)的长效制剂为主要联合用药类别。结论:医院抗高血压药物联合用药基本合理,基本达到《中国高血压防治指南》要求,但也存在某些联合用药不规范方案,需要进一步改善。

Objective： To analyze the combined application of anti-hypertensive drugs and the rationality. Methods： Totally 460 antihypertensive patients were treated with eombination of drugs from January 2010 to January 2011. The medical records of these patients were analyzed according to the dosing regimen, drug classes, category, and clinical efficacy. Results： The double and triple drug combinations were the main use form, accounting 64. 13% and 33.26% , respectively; the average effective rates were 85.42% and 81.70% . The main regimens of double drug combinations were CCB with ACEI, CCB with β-receptor antagonist, and ACEI with β-receptor antagonists; the triple drug combinations were mainly ACEI, diuretics and calcium antagonists, and ACEI, calcium an- tagonist and β-receptor antagonist. Conclusion： In the hospital, anti-hypertensive drug combination is generally rational based on the requirements of ＇ China Hypertension Prevention Guide＇ , but some non-standardarized combinations need to be improved.